The clinical efficacy of AG NPP709 (Synatura^®) in patients with chronic bronchitis type stable chronic obstructive pulmonary disease.

ABSTRACT:

Background

AG NPP709 (Synatura^®) has been demonstrated to be efficacious in decreasing cough and sputum in patients with acute upper respiratory infection and chronic inflammatory bronchitis. The aim of this study was to evaluate the efficacy of AG NPP709 in patients with chronic bronchitis type chronic obstructive pulmonary disease (COPD).

Methods

This was a prospective, open-label, single-arm clinical trial (NCT03623282). Chronic bronchitis type COPD patients aged >40 years were enrolled. The primary endpoint was improvement on the CAT scores between the baseline visit and week 12. The secondary endpoints were the effect of AG NPP709 on the pulmonary function and systemic inflammation, as indexed by CRP, fibrinogen, IL-6, TNF-α and IL-33 levels.

Results

T

SUBMITTER: Lee EG 

PROVIDER: S-EPMC7330415 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature